Could a malaria drug ease lingering lyme symptoms?
NCT ID NCT07230028
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding hydroxychloroquine (a malaria drug) to standard doxycycline treatment can reduce long-term complaints in adults with Lyme disease. Fifty participants will take either hydroxychloroquine or a placebo twice daily for 28 days, with follow-up visits over a year. The goal is to see if the combination improves quality of life and physical symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hydroxychloroquine (Plaquenil) added to doxycycline
- What this could lead to
- If it works, this could point toward a better treatment for lingering Lyme symptoms, improving quality of life for patients.
- What could go wrong
- This is a small pilot study with only 50 people, so results may not apply widely. The treatment is short-term and may not help everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYME BORRELIOSIS, NERVOUS SYSTEM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Earthworm enzyme trial aims to ease long covid and chronic fatigue
- Can a mask that pulses light and sound ease chronic pain?
- Zapping a nerve in the ear might ease lingering lyme disease symptoms
- Lyme disease mystery: do bacteria lurk after antibiotics?
- Lyme disease trial withdrawn before it even started
- Massive study aims to unlock secrets of brain inflammation diseases